The Pharmabiotics 2022 Conference & Partnering Event was held on 20-21 April 2022 in Lyon, France. Nearly 200 delegates from industry and academia joined together to discuss a range of topics focusing on microbiome regulatory science, multi-omics standardization and harmonization, genetically modified organisms as well as intellectual property considerations for the microbiome-based medicinal product development field.
This year’s edition was opened by PRI President Bruno Pot – who spoke about the increasing importance that microbiome science has taken in our understanding of health and disease.
Following the opening address, Georges Rawadi (formerly CEO of YSOPIA Bioscience) moderated the keynote panel discussion focusing on what microbiome drug developers can learn from those in the advance therapies field. The panel was titled, “ATMPs to Microbiome-based Products: What can we learn from the past and apply to the future?”
The 2-day Conference saw more than 30 presentations covering nearly the entire continuum of microbiome-based product development, from fundamental and applied research, through preclinical and clinical trials, right through to market authorization.
